The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery – subgroup analyses from 17,701 patients in the XAMOS study

Vascular Health and Risk Management

Volumn 12, Issue , 2016, Pages 209-218

  Haas, Sylvia ^a   Holberg, Gerlind ^b   Kreutz, Reinhold ^c   Lassen, Michael Rud ^d   Mantovani, Lorenzo ^e   Haupt, Verena ^f   Vogtländer, Kai ^b   Turpie, Alexander G G ^g  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b BAYER PHARMA AG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f BAYER AG   (Germany)

^g Hamilton Public Health Services   (Canada)

Author keywords

Bleeding event; Rivaroxaban; Thromboprophylaxis; VTE prevention

Indexed keywords

DABIGATRAN ETEXILATE; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOLYTIC AGENT;

ADULT; ANESTHESIA; ARTICLE; BLEEDING; COMPRESSION STOCKING; COMPRESSION THERAPY; EPIDURAL ANESTHESIA; GENERAL ANESTHESIA; HIP SURGERY; HUMAN; KNEE SURGERY; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); ORTHOPEDIC SURGERY; PHASE 4 CLINICAL TRIAL (TOPIC); SPINAL ANESTHESIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; ADVERSE EFFECTS; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; INCIDENCE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; REGIONAL ANESTHESIA; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANESTHESIA, CONDUCTION; ANESTHESIA, GENERAL; BLOOD COAGULATION; DRUG ADMINISTRATION SCHEDULE; FACTOR XA INHIBITORS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INCIDENCE; ORTHOPEDIC PROCEDURES; RISK FACTORS; RIVAROXABAN; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84970031416     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S100293     Document Type: Article

References (20)

1. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e278S-e325S.
2. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.
3. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.
4. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-1680.
5. Turpie AGG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011;105:444-453.
6. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-39.
7. Turpie AGG, Haas S, Kreutz R, et al. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thromb Haemost. 2014;111:94-102.
8. Rosencher N, Bonnet MP, Sessler DI. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia. 2007;62:1154-1160.
9. Turpie AGG, Bauer KA, Eriksson BI, et al; Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833-1840.
10. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. Br Med J. 2000;321:1493.
11. European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products for Prevention of Venous Thromboembolism (VTE) in Patients Undergoing High VTE-Risk Surgery. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127902.pdf. Accessed January 20, 2016.
12. Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003;124:379S-385S.
13. Bayer Pharma AG. Xarelto® (Rivaroxaban) Summary of Product Characteristics. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Accessed January 20, 2016.
14. Gogarten W, Vandermeulen E, Van Aken H, et al; European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010;27:999-1015.
15. Rosencher N, Llau JV, Mueck W, Loewe A, Berkowitz SD, Homering M. Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiol Scand. 2013;57:565-572.
16. Macfarlane AJ, Prasad GA, Chan VW, Brull R. Does regional anaesthesia improve outcome after total hip arthroplasty? A systematic review. Br J Anaesth. 2009;103:335-345.
17. Patel N, Khakha R, Gibbs J. Review article: anti-embolism stockings. J Orthop Surg (Hong Kong). 2013;21:361-364.
18. Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 2013;128:1003-1020.
19. Kakkos SK, Warwick D, Nicolaides AN, Stansby GP, Tsolakis IA. Combined (mechanical and pharmacological) modalities for the prevention of venous thromboembolism in joint replacement surgery. J Bone Joint Surg Br. 2012;94:729-734.
20. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, editors. Advances in Inflammatory Research. New York: Raven Press; 1984:1-7.